Mylan: Treating Debt And Intangibles

In today’s world, it is shortsighted to think that infectious diseases cannot cross borders. By allowing developing countries access to generic drugs, we not only help improve health in those nations, we also help ourselves control these debilitating and often deadly diseases. Ron Wyden
Mylan (MYL) is a large generics manufacturer whose balance sheet is bloated by intangible assets and debt. The company is gradually reducing debt and amortizing goodwill, and it could be a turnaround story.

Click here to view the original article.